Celldex Therapeutics Files Q1 2025 10-Q
Ticker: CLDX · Form: 10-Q · Filed: May 8, 2025 · CIK: 744218
| Field | Detail |
|---|---|
| Company | Celldex Therapeutics, Inc. (CLDX) |
| Form Type | 10-Q |
| Filed Date | May 8, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biotech
TL;DR
Celldex Q1 2025 10-Q filed. Financials updated.
AI Summary
Celldex Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details the company's financial position, including common stock, retained earnings, and additional paid-in capital as of March 31, 2025, and compares it to the previous fiscal year-end. The company is involved in the field of in vitro & in vivo diagnostic substances.
Why It Matters
This filing provides investors with an update on Celldex Therapeutics' financial health and performance for the first quarter of 2025, crucial for understanding the company's operational status and future prospects.
Risk Assessment
Risk Level: low — This is a routine quarterly financial filing with no immediate red flags or significant new disclosures.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 20250508 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- Celldex Therapeutics, Inc. (company) — Filer of the 10-Q
- March 31, 2025 (date) — End of the reporting period
- 20250508 (date) — Filing date
- 0000744218 (company) — Central Index Key for Celldex Therapeutics, Inc.
FAQ
What were the key financial components reported as of March 31, 2025?
The filing indicates reporting on common stock, retained earnings, additional paid-in capital, accumulated translation adjustment, accumulated other comprehensive income, and accumulated net unrealized investment gain/loss as of March 31, 2025.
How does the financial data for March 31, 2025, compare to the previous fiscal year-end?
The filing includes data points for both March 31, 2025, and December 31, 2024, allowing for comparison of retained earnings, additional paid-in capital, and other comprehensive income items.
What is Celldex Therapeutics, Inc.'s Standard Industrial Classification (SIC) code?
Celldex Therapeutics, Inc.'s SIC code is 2835, which corresponds to 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES'.
When was Celldex Therapeutics, Inc. previously known by other names?
The company was formerly known as AVANT IMMUNOTHERAPEUTICS INC (name change date 19980828) and T CELL SCIENCES INC (name change date 19920703).
What is the business address and phone number for Celldex Therapeutics, Inc.?
The business address is 53 FRONTAGE ROAD, SUITE 220, HAMPTON, NJ 08827, and the business phone number is 908-200-7500.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding Celldex Therapeutics, Inc. (CLDX).